A citation-based method for searching scientific literature

Soley Bayraktar, Banu Arun. Breast 2017
Times Cited: 26







List of co-cited articles
77 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
498
15

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
875
15

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Henry T Lynch, Susan L Neuhausen, Laura van 't Veer, Judy E Garber, Gareth R Evans, Steven A Narod, Claudine Isaacs, Ellen Matloff,[...]. J Clin Oncol 2004
706
11

Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
J Peto, N Collins, R Barfoot, S Seal, W Warren, N Rahman, D F Easton, C Evans, J Deacon, M R Stratton. J Natl Cancer Inst 1999
636
11

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Rossella Graffeo, Luca Livraghi, Olivia Pagani, Aron Goldhirsch, Ann H Partridge, Judy E Garber. Breast Cancer Res Treat 2016
35
11

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Nadine Tung, Nancy U Lin, John Kidd, Brian A Allen, Nanda Singh, Richard J Wenstrup, Anne-Renee Hartman, Eric P Winer, Judy E Garber. J Clin Oncol 2016
259
11

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Mary B Daly, Robert Pilarski, Michael Berry, Saundra S Buys, Meagan Farmer, Susan Friedman, Judy E Garber, Noah D Kauff, Seema Khan, Catherine Klein,[...]. J Natl Compr Canc Netw 2017
296
11

Population genetic testing for cancer susceptibility: founder mutations to genomes.
William D Foulkes, Bartha Maria Knoppers, Clare Turnbull. Nat Rev Clin Oncol 2016
63
11

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
696
11


Use of BRCA Mutation Test in the U.S., 2004-2014.
Fangjian Guo, Jacqueline M Hirth, Yu-Li Lin, Gwyn Richardson, Lyuba Levine, Abbey B Berenson, Yong-Fang Kuo. Am J Prev Med 2017
37
11

National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
Christopher P Childers, Kimberly K Childers, Melinda Maggard-Gibbons, James Macinko. J Clin Oncol 2017
141
11

Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.
Alfons Meindl, Nina Ditsch, Karin Kast, Kerstin Rhiem, Rita K Schmutzler. Dtsch Arztebl Int 2011
78
7


Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
849
7

Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.
Kelly A Metcalfe, Nida Mian, Melissa Enmore, Aletta Poll, Marcia Llacuachaqui, Sonia Nanda, Ping Sun, Kevin S Hughes, Steven A Narod. Breast Cancer Res Treat 2012
57
7

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
7

Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
Bruce G Haffty, Elizabeth Harrold, Atif J Khan, Pradip Pathare, Tanya E Smith, Bruce C Turner, Peter M Glazer, Barbara Ward, Daryl Carter, Ellen Matloff,[...]. Lancet 2002
195
7

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
H Meijers-Heijboer, B van Geel, W L van Putten, S C Henzen-Logmans, C Seynaeve, M B Menke-Pluymers, C C Bartels, L C Verhoog, A M van den Ouweland, M F Niermeijer,[...]. N Engl J Med 2001
632
7

Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2.
V R Grann, W Whang, J S Jacobson, D F Heitjan, K H Antman, A I Neugut. J Clin Oncol 1999
56
7

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
Victor R Grann, Priya R Patel, Judith S Jacobson, Ellen Warner, Daniel F Heitjan, Maxine Ashby-Thompson, Dawn L Hershman, Alfred I Neugut. Breast Cancer Res Treat 2011
69
7

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
582
7

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
7


A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.
Rebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, Amit M Oza, Patricia LoRusso, Manish R Patel, Susan M Domchek, Judith Balmaña, Yvette Drew, Lee-May Chen,[...]. Clin Cancer Res 2017
130
7

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
7

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
7

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
7

PARP inhibitors in ovarian cancer.
J A Ledermann. Ann Oncol 2016
76
7

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
Geoffrey Kim, Gwynn Ison, Amy E McKee, Hui Zhang, Shenghui Tang, Thomas Gwise, Rajeshwari Sridhara, Eunice Lee, Abraham Tzou, Reena Philip,[...]. Clin Cancer Res 2015
300
7

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
Johann de Bono, Ramesh K Ramanathan, Lida Mina, Rashmi Chugh, John Glaspy, Saeed Rafii, Stan Kaye, Jasgit Sachdev, John Heymach, David C Smith,[...]. Cancer Discov 2017
214
7

Genetics of breast cancer: a topic in evolution.
S Shiovitz, L A Korde. Ann Oncol 2015
132
7

A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Saundra S Buys, John F Sandbach, Amanda Gammon, Gayle Patel, John Kidd, Krystal L Brown, Lavania Sharma, Jennifer Saam, Johnathan Lancaster, Mary B Daly. Cancer 2017
183
7

Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery.
Irene T Ma, Richard J Gray, Nabil Wasif, Kristina A Butler, Jeffrey L Cornella, Javier F Magrina, Paul M Magtibay, William J Casey, Raman Mahabir, Alanna M Rebecca,[...]. Ann Surg Oncol 2017
13
15

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Fergus J Couch, Steven N Hart, Priyanka Sharma, Amanda Ewart Toland, Xianshu Wang, Penelope Miron, Janet E Olson, Andrew K Godwin, V Shane Pankratz, Curtis Olswold,[...]. J Clin Oncol 2015
367
7

Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Zora Baretta, Simone Mocellin, Elena Goldin, Olufunmilayo I Olopade, Dezheng Huo. Medicine (Baltimore) 2016
72
7


Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
Michael G Schrauder, Lisa Brunel-Geuder, Lothar Häberle, Marius Wunderle, Juliane Hoyer, André Reis, Rüdiger Schulz-Wendtland, Matthias W Beckmann, Michael P Lux. Breast 2017
17
11


Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.
Carmine Pinto, Maria Angela Bella, Ettore Capoluongo, Paola Carrera, Claudio Clemente, Nicoletta Colombo, Laura Cortesi, Gaetano De Rosa, Francesca Fenizia, Maurizio Genuardi,[...]. Future Oncol 2016
18
11

Fanconi anaemia and cancer: an intricate relationship.
Grzegorz Nalepa, D Wade Clapp. Nat Rev Cancer 2018
134
7

Current status of poly(ADP-ribose) polymerase inhibitors and future directions.
Akihiro Ohmoto, Shinichi Yachida. Onco Targets Ther 2017
72
7

DNA damage sensing by the ATM and ATR kinases.
Alexandre Maréchal, Lee Zou. Cold Spring Harb Perspect Biol 2013
631
7

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
7

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
7

A comprehensive BRCA1/2 NGS pipeline for an immediate Copy Number Variation (CNV) detection in breast and ovarian cancer molecular diagnosis.
Paola Concolino, Roberta Rizza, Flavio Mignone, Alessandra Costella, Donatella Guarino, Ilaria Carboni, Ettore Capoluongo, Concetta Santonocito, Andrea Urbani, Angelo Minucci. Clin Chim Acta 2018
17
11

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
7

A Whole Germline BRCA2 Gene Deletion: How to Learn from CNV In Silico Analysis.
Giovanni Luca Scaglione, Paola Concolino, Maria De Bonis, Elisa De Paolis, Angelo Minucci, Gabriella Ferrandina, Giovanni Scambia, Ettore Capoluongo. Int J Mol Sci 2018
7
28

Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
Allison W Kurian, Yun Li, Ann S Hamilton, Kevin C Ward, Sarah T Hawley, Monica Morrow, M Chandler McLeod, Reshma Jagsi, Steven J Katz. J Clin Oncol 2017
133
7

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Kelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, Siegal Sadetzki, Susan J Ramus, Beth Y Karlan, Diether Lambrechts, Evelyn Despierre, Daniel Barrowdale, Lesley McGuffog,[...]. JAMA 2012
371
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.